Istaroxime是一款潜在“first-in-class”疗法,具有双重作用机制,旨在改善心脏收缩和舒张...查看全文
$Windtree疗法(WINT)$ S-3 Registration statement under Securities Act of 1933 Accession Number: 0001437749-21-029193 Act: 33 Size: 929 KB 网页链接
$Windtree疗法(WINT)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001437749-21-027198 Size: 5 KB 网页链接
$Windtree疗法(WINT)$ 内部交易: 2021-11-18,总裁 and CEO,Fraser Craig ,买入,930普通股, $1.61
$Windtree疗法(WINT)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001437749-21-027085 Size: 5 KB 网页链接
$Windtree疗法(WINT)$ 8-K Current report, items 2.02, 8.01, and 9.01 Accession Number: 0001437749-21-026141 Act: 34 Size: 5 MB 网页链接
$Windtree疗法(WINT)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001437749-21-026140 Act: 34 Size: 4 MB 网页链接
$Windtree Therapeutics Inc(WINT)$ 内部交易: 2021-10-22,总裁 and CEO,Fraser Craig ,买入,3000普通股, $1.90
$Windtree Therapeutics Inc(WINT)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001437749-21-024196 Size: 5 KB 网页链接
$Windtree Therapeutics Inc(WINT)$ 内部交易: 2021-10-19,总裁 and CEO,Fraser Craig ,买入,3000普通股, $1.91
$Windtree Therapeutics Inc(WINT)$ 内部交易: 2021-10-19,Director,Huang James ,买入,50000普通股, $1.90